News

Exercise pumps up chemotherapy completion rates for breast cancer patients


 

References

Compared with usual care, a moderate- to high-intensity exercise intervention had beneficial effects on chemotherapy completion rates, symptom burden, and return-to-work rates among women with breast cancer who were undergoing adjuvant chemotherapy, according to a study published online April 27 in the Journal of Clinical Oncology.

For the multicenter Physical Exercise During Adjuvant Chemotherapy Effectiveness Study (PACES), 230 women (mean age 51 years) with breast cancer who were undergoing adjuvant chemotherapy were randomized to participate in a high- to moderate-intensity exercise program supervised by physical therapists (n = 76), a low-intensity home-based program (n = 77), or the usual care group (n = 77).

©Luka8au/thinkstockphotos.com

Dose adjustments in the chemotherapy regimen were less frequent in the moderate- to high-intensity exercise group (12%) than in the usual care or low-intensity groups (both 34%, P = .002). Patients in the exercise interventions were more likely to return to work by the 6-month follow up than those with usual care, wrote Ms. Hanna van Waart, a doctoral candidate at the Netherlands Cancer Institute, Amsterdam, and colleagues (J. Clin. Oncol. 2015 Apr. 27 [doi:10.1200/JCO.2014.59.1081]).

“This not only has financial implications, but also carries meaning in terms of quality of life and a sense of return to normalcy,” they wrote.

At completion of chemotherapy, patients from both activity groups reported significantly better physical functioning, less nausea and vomiting, and less pain than did those in the usual care group.

Recommended Reading

Alzheimer’s drug improves cognitive function after RT for brain tumors
MDedge Hematology and Oncology
Task Force: Start biennial mammograms at age 50
MDedge Hematology and Oncology
VIDEO: Circulating tumor DNA testing shows real-world limits
MDedge Hematology and Oncology
PD-L1 blockade breaks through triple-negative breast cancer
MDedge Hematology and Oncology
AACR: Metformin survival benefit shaky in pancreatic cancer
MDedge Hematology and Oncology
Oophorectomy improves survival after breast cancer in BRCA1 carriers
MDedge Hematology and Oncology
ELCC: NSCLC mutation testing highlights ctDNA’s limitations
MDedge Hematology and Oncology
Encouraging outcomes continue following CAR T cell therapy in kids
MDedge Hematology and Oncology
CVD risk persists for 40 years in Hodgkin’s survivors
MDedge Hematology and Oncology
VIDEO: NAFLD increasingly causing U.S. hepatocellular carcinomas
MDedge Hematology and Oncology